Definitive Healthcare (NASDAQ:DH) Issues Q4 2025 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its fourth quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.050-0.060 for the period, compared to the consensus estimate of 0.050. The company issued revenue guidance of $59.0 million-$60.0 million, compared to the consensus revenue estimate of $59.1 million. Definitive Healthcare also updated its FY 2025 guidance to 0.230-0.240 EPS.

Definitive Healthcare Stock Up 10.6%

NASDAQ:DH traded up $0.28 during mid-day trading on Friday, hitting $2.93. The stock had a trading volume of 502,544 shares, compared to its average volume of 251,544. Definitive Healthcare has a twelve month low of $2.15 and a twelve month high of $5.68. The stock has a 50-day simple moving average of $3.46 and a two-hundred day simple moving average of $3.57. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $419.41 million, a PE ratio of -1.75 and a beta of 1.61.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.14%. The company had revenue of $60.05 million for the quarter, compared to the consensus estimate of $59.51 million. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS. Q4 2025 guidance at 0.050-0.060 EPS. On average, equities research analysts anticipate that Definitive Healthcare will post 0.16 EPS for the current year.

Analysts Set New Price Targets

DH has been the topic of a number of analyst reports. William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a research note on Thursday. Stifel Nicolaus raised their target price on Definitive Healthcare from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Robert W. Baird set a $4.00 price target on Definitive Healthcare in a report on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $4.28.

Institutional Trading of Definitive Healthcare

A number of large investors have recently made changes to their positions in DH. Raymond James Financial Inc. purchased a new position in Definitive Healthcare during the 2nd quarter worth approximately $32,000. Bayesian Capital Management LP acquired a new stake in shares of Definitive Healthcare in the second quarter valued at approximately $55,000. Tower Research Capital LLC TRC boosted its holdings in shares of Definitive Healthcare by 357.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,233 shares of the company’s stock valued at $67,000 after acquiring an additional 13,466 shares during the period. Creative Planning grew its position in shares of Definitive Healthcare by 41.7% during the second quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after acquiring an additional 8,428 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Definitive Healthcare by 17.8% in the 2nd quarter. Invesco Ltd. now owns 72,900 shares of the company’s stock valued at $284,000 after acquiring an additional 11,029 shares during the period. 98.67% of the stock is owned by institutional investors and hedge funds.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.